Scholars@Duke
Hannah Dzimitrowicz McManus

Hannah Dzimitrowicz McManus

Assistant Professor of Medicine
Medicine, Medical Oncology

Selected Publications

Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.

Journal Article Oncologist · October 3, 2024 BACKGROUND: Even though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). MATERIALS AND METHODS: ... Full text Link to item Cite

FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · March 20, 2024 <p>Distributions of pain at study enrollment by race. <b>A,</b> Distributions of scores on the EORTC pain scale by race. <b>B,</b> Distributions of scores on the average pain scale by race. <b>C,</b> Distri ... Full text Cite

Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · March 20, 2024 <div>Abstract<p>Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions o ... Full text Cite

FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · March 20, 2024 <p>Distributions of pain at study enrollment by race. <b>A,</b> Distributions of scores on the EORTC pain scale by race. <b>B,</b> Distributions of scores on the average pain scale by race. <b>C,</b> Distri ... Full text Cite

Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · March 20, 2024 <div>Abstract<p>Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions o ... Full text Cite

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.

Journal Article Cancer Res Commun · January 8, 2024 UNLABELLED: Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the associati ... Full text Link to item Cite

FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Distributions of pain at study enrollment by race. <b>A,</b> Distributions of scores on the EORTC pain scale by race. <b>B,</b> Distributions of scores on the average pain scale by race. <b>C,</b> Distri ... Full text Cite

TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Average pain at study enrollment by disease state at enrollment and self-reported race (<i>N</i> = 4 pain scales)</p> ... Full text Cite

TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Average pain at study enrollment by disease state at enrollment and self-reported race (<i>N</i> = 4 pain scales)</p> ... Full text Cite

Supplementary Figure S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Longitudinal observation status of questionnaires and reasons for being off-study throughout follow-up</p> ... Full text Cite

Supplementary Figure S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Longitudinal observation status of questionnaires and reasons for being off-study throughout follow-up</p> ... Full text Cite

Supplementary Table S7 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline average pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

Supplementary Table S8 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline worst pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

Supplementary Table S6 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline EORTC pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

Supplementary Table S9 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline bone pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

Supplementary Table S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Number of participants receiving each therapy category between 3 months prior to enrollment and any time after enrollment stratified by disease state and self-reported race (N=19 therapy categories), N (%)</p> ... Full text Cite

Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <div>Abstract<p>Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions o ... Full text Cite

Supplementary Table S6 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline EORTC pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Stratified analyses for the association between pain scales at enrollment and death, IRONMAN Registry 2017–2023</p> ... Full text Cite

Supplementary Table S7 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline average pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Further information guiding the choice of methods and a glossary of technical terms</p> ... Full text Cite

TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Cohort demographic and clinical characteristics by self-reported race (<i>N</i> = 879), 2017–2023</p> ... Full text Cite

Supplementary Table S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Number of participants receiving each therapy category between 3 months prior to enrollment and any time after enrollment stratified by disease state and self-reported race (N=19 therapy categories), N (%)</p> ... Full text Cite

Supplementary Table S5 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>80th percentile survival and 95% confidence intervals for each category of pain at study enrollment</p> ... Full text Cite

TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Cohort demographic and clinical characteristics by self-reported race (<i>N</i> = 879), 2017–2023</p> ... Full text Cite

Supplementary Table S8 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline worst pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Kaplan–Meier curves for overall survival by pain categories at study enrollment, IRONMAN Registry 2017–2023. <b>A,</b> Kaplan–Meier curve for the EORTC pain scale. <b>B,</b> Kaplan–Meier curve for the average pain s ... Full text Cite

Supplementary Table S5 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>80th percentile survival and 95% confidence intervals for each category of pain at study enrollment</p> ... Full text Cite

FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Kaplan–Meier curves for overall survival by pain categories at study enrollment, IRONMAN Registry 2017–2023. <b>A,</b> Kaplan–Meier curve for the EORTC pain scale. <b>B,</b> Kaplan–Meier curve for the average pain s ... Full text Cite

Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Further information guiding the choice of methods and a glossary of technical terms</p> ... Full text Cite

Supplementary Table S9 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Baseline bone pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure</p> ... Full text Cite

TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>HRs and 95% CIs for the association between baseline and longitudinal pain scales and death, IRONMAN Registry 2017–2023 (<i>N</i> = 879; 137 deaths in White participants, 37 deaths in Black participants)</p> ... Full text Cite

TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>HRs and 95% CIs for the association between baseline and longitudinal pain scales and death, IRONMAN Registry 2017–2023 (<i>N</i> = 879; 137 deaths in White participants, 37 deaths in Black participants)</p> ... Full text Cite

TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Other · January 8, 2024 <p>Stratified analyses for the association between pain scales at enrollment and death, IRONMAN Registry 2017–2023</p> ... Full text Cite

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.

Journal Article Clin Genitourin Cancer · December 2023 INTRODUCTION: Biomarkers are needed to identify patients with metastatic renal cell carcinoma (mRCC) most likely to benefit from immune checkpoint inhibitors. We examined associations between radiographically assessed body composition (BC) variables and bo ... Full text Link to item Cite

Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis.

Conference Clin Genitourin Cancer · December 2023 BACKGROUND: To evaluate effect and outcomes of combination primary immunotherapy (IO) and nephrectomy for advanced renal cell carcinoma (RCC). METHODS: We conducted a multicenter, retrospective analysis of patients with advanced/metastatic RCC who received ... Full text Link to item Cite

Reply to E. Hindié.

Journal Article J Clin Oncol · August 1, 2023 Full text Link to item Cite

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

Journal Article BMC Cancer · March 23, 2023 INTRODUCTION: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among ... Full text Link to item Cite

End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.

Journal Article JCO Oncol Pract · February 2023 PURPOSE: New therapies including oral anticancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, little is known about the quality of end-of-life (EOL) care and systemic therapy use at EOL in patients ... Full text Link to item Cite

Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.

Journal Article Clin Genitourin Cancer · February 2023 BACKGROUND: In patients with renal cell carcinoma (RCC) on cabozantinib, venous thromboembolism (VTE) management remains challenging due to limited safety data regarding direct oral anticoagulants (DOACs) use in conjunction with cabozantinib. We investigat ... Full text Link to item Cite

Reply to L. Marandino et al.

Journal Article J Clin Oncol · July 1, 2022 Full text Link to item Cite

Bridging New Technology Into Clinical Practice With Mobile Apps, Electronic Patient-Reported Outcomes, and Wearables.

Journal Article Am Soc Clin Oncol Educ Book · April 2022 With sophisticated mobile and wearable technologies available, there has been interest in leveraging these devices to help gather and analyze patient-generated health data (PGHD). This information could be used to better address health concerns, aid in tre ... Full text Link to item Cite

Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.

Conference Journal of Clinical Oncology · February 20, 2022 300 Background: Although oral anti-cancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC), most patients still die from the disease. High quality end-of-life (EOL) care remains a cruc ... Full text Cite

Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).

Conference Journal of Clinical Oncology · February 20, 2022 334 Background: IO, either as combination therapy in the frontline or monotherapy in the second line, has improved outcomes for patients with advanced RCC. With the movement away from upfront CN, limited data are available on the ... Full text Cite

Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.

Conference Journal of Clinical Oncology · February 20, 2022 390 Background:The concept of primary systemic therapy has gained increasing traction in the management of metastatic and locally advanced Renal Cell Carcinoma (RCC). Most series have evaluated the use of tyrosine-kinase inhibito ... Full text Cite

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.

Journal Article JAMA oncology · December 2021 ImportancePatients with brain metastases from renal cell carcinoma (RCC) have been underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib shows robust clinical activity in metastatic RCC, but its effect on bra ... Full text Cite

Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.

Journal Article Cancer Med · December 2021 BACKGROUND: It is unclear whether patients with renal cell carcinoma (RCC) are routinely assessed for recurrence risk post-nephrectomy and whether patients at high recurrence risk are seen by providers who can evaluate candidacy for adjuvant systemic thera ... Full text Link to item Cite

Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).

Conference Journal of Clinical Oncology · May 20, 2021 e16515 Background: PC remains standard first-line (1L) therapy for aUC. Approximately 15% of pts exhibit primary resistance (P-R) to PC and ∼25% progress by 4 months. PD(L)1 inhibitors yield objective response rates (ORR) of ∼20% ... Full text Cite

Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).

Conference Journal of Clinical Oncology · February 20, 2021 291 Background: Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. Despite cabo improving RCC outcomes, VTE management in these patients remains a challenge, partly due to poor understandin ... Full text Cite

Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.

Conference Journal of Clinical Oncology · February 20, 2021 310 Background: Cabo shows robust clinical activity in mRCC. Patients (pts) with BM have been underrepresented in clinical trials and effective systemic therapy is lacking. We retrospectively characterized the clinical activity a ... Full text Cite

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.

Journal Article J Immunother Cancer · March 2020 BACKGROUND: There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) and advanced urological cancers as they are generally excluded from clinical trials due to risk of exacerbat ... Full text Link to item Cite

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Journal Article Lancet Oncol · April 2019 BACKGROUND: Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sough ... Full text Link to item Cite

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.

Journal Article J Oncol Pract · December 2017 PURPOSE: The 21-gene recurrence score (RS) assay is used to help formulate adjuvant chemotherapy recommendations for patients with estrogen receptor-positive, early-stage breast cancer. Most frequently, medical oncologists order RS after surgery. Results t ... Full text Link to item Cite

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.

Journal Article J Clin Oncol · October 10, 2016 Purpose Ado-trastuzumab emtansine (T-DM1) is currently approved for treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane. However, there are no ... Full text Link to item Cite

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Journal Article Oncologist · May 2014 The aim of this study was to assess the frequency of potentially actionable genomic alterations in breast cancer that could be targeted with approved agents or investigational drugs in clinical trials using a next-generation sequencing-based genomic profil ... Full text Link to item Cite